Alector in Spotlight at TD Cowen With Future Hinged on Brain-Delivery Tech

SOUTH SAN FRANCISCO, Calif. – February 24, 2026 – Clinical-stage biotechnology company Alector, Inc. is preparing to take the stage at the prestigious TD Cowen 46th Annual Health Care Conference next week, but this will be no ordinary corporate update. The company's presentation, scheduled for March 3, is poised to be a critical moment for investors and the broader neuroscience community as Alector seeks to redefine its path forward after a significant clinical setback.

Less than five months after its lead drug candidate for a rare form of dementia failed a pivotal Phase 3 trial, Alector finds itself at a strategic crossroads. The upcoming presentation offers management a high-profile platform to articulate its revised vision, one that now leans heavily on the promise of its earlier-stage pipeline and a proprietary technology designed to overcome one of the greatest challenges in neuroscience: delivering drugs into the brain.

The Shadow of a Setback

The context for Alector's presentation is inescapably shaped by the events of October 2025. The company announced the disappointing topline results from its INFRONT-3 study of latozinemab, a therapy for frontotemporal dementia in patients with a progranulin gene mutation (FTD-GRN). While the drug successfully increased levels of the target protein, progranulin, it crucially failed to slow the devastating progression of the disease. The clinical co-primary endpoint was not met, and key biological markers of disease progression also showed no improvement.

The fallout was swift and severe. Alector's stock plummeted by nearly 50% in after-hours trading following the news. The company promptly discontinued the program, including its long-term extension studies, and announced a painful but necessary corporate restructuring. The workforce was reduced by approximately 49% as Alector moved to conserve capital and realign its resources with a reshaped set of priorities. This setback was compounded by the fact that it followed the failure of another Alzheimer's candidate, AL002, in a Phase 2 trial in late 2024.

With its most advanced asset shelved, the pressure is on Alector to convince stakeholders that its scientific foundation remains sound and that its remaining programs hold the potential for a breakthrough in the notoriously difficult field of neurodegeneration.

A Strategic Pivot to the Pipeline

At the TD Cowen conference, Alector is expected to shift the narrative firmly toward the future. The company’s strategy now rests on two main pillars: a mid-stage Alzheimer's candidate being developed with a major pharmaceutical partner and, more significantly, a portfolio of preclinical assets powered by its proprietary Alector Brain Carrier (ABC) platform.

The first pillar is nivisnebart (also known as AL101), an investigational antibody for early Alzheimer's disease being co-developed with GSK. Like the failed latozinemab, nivisnebart is designed to elevate progranulin levels in the brain. However, the company has emphasized that it is a distinct molecule with different properties that may make it suitable for more prevalent neurodegenerative diseases. Enrollment in the global Phase 2 PROGRESS-AD trial was completed in April 2025, and a crucial independent interim analysis is anticipated in the first half of 2026. This upcoming data readout represents a major near-term catalyst and a test of the progranulin hypothesis in the far larger Alzheimer's market.

Beyond nivisnebart, Alector's long-term value proposition is now intrinsically linked to its ABC technology, a platform that could unlock a new generation of treatments for brain diseases.

The Promise of the Alector Brain Carrier

The central challenge in treating neurological disorders is the blood-brain barrier (BBB), a highly selective membrane that protects the brain from toxins but also blocks more than 98% of potential therapeutic drugs. Alector's ABC platform is designed to act as a molecular Trojan horse, smuggling large-molecule therapies across this formidable barrier.

The technology utilizes a mechanism called receptor-mediated transcytosis, specifically targeting a unique epitope on the transferrin receptor, which is abundant on the cells that form the BBB. By binding to this receptor, an ABC-enabled drug can be actively transported into the brain.

Alector has highlighted the platform's versatility, having demonstrated its functionality across three different types of therapies: antibodies, enzymes, and small interfering RNA (siRNA). This multi-modal capability suggests the platform is not a one-off solution but a scalable technology that could be applied to a wide range of neurological targets. The potential benefits are significant: achieving therapeutic concentrations in the brain with lower peripheral doses, which could improve safety, reduce costs, and allow for more convenient subcutaneous administration.

The company is advancing several preclinical programs built on this technology:

• AL137: An ABC-enabled anti-amyloid beta antibody for Alzheimer's disease. Alector aims to file an Investigational New Drug (IND) application to begin human trials in 2026.

• AL050: An ABC-enabled enzyme replacement therapy for Parkinson's disease patients with GBA gene mutations. The goal is to deliver a functional GCase enzyme to the brain, with an IND submission targeted for 2027.

• ABC-enabled siRNA platform: A suite of programs using gene-silencing technology to target the root causes of disease, including therapies aimed at tau for Alzheimer's and FTD, alpha-synuclein for Parkinson's, and NLRP3 for neuroinflammation.

Navigating a Treacherous Market

Alector's strategic pivot is taking place against the backdrop of a neurodegenerative disease market that is both immensely promising and fraught with peril. The market was valued at nearly $60 billion in 2025 and is projected to grow substantially, driven by an aging global population. However, the field is a graveyard for failed drug candidates, with clinical trial failure rates exceeding 99% for Alzheimer's disease over the past two decades.

Recent approvals of disease-modifying therapies like Leqembi from Biogen and Eisai have injected new optimism and commercial momentum into the space, but they have also raised the competitive stakes. Alector competes in a crowded arena with industry giants like Eli Lilly and specialized biotech firms such as Denali Therapeutics and Voyager Therapeutics, all pursuing novel approaches to these complex diseases.

For Alector, the TD Cowen presentation is an opportunity to re-assert its unique value proposition. While investor sentiment is justifiably cautious, with most analyst ratings hovering around "Hold," the company's financial position provides a crucial buffer. Alector reported approximately $291.1 million in cash as of September 30, 2025, which it projects will fund operations through 2027. This financial runway gives the company time to execute its pivot and advance its ABC-enabled programs toward the clinic. All eyes will be on management to deliver a compelling case that, despite past stumbles, the company's scientific engine and innovative delivery technology hold the key to its future success.